SG Americas Securities LLC Sells 9,896 Shares of Disc Medicine, Inc. $IRON

SG Americas Securities LLC lowered its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 46.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,226 shares of the company’s stock after selling 9,896 shares during the quarter. SG Americas Securities LLC’s holdings in Disc Medicine were worth $718,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. lifted its position in shares of Disc Medicine by 184.8% during the fourth quarter. Invesco Ltd. now owns 61,070 shares of the company’s stock worth $4,850,000 after purchasing an additional 39,627 shares in the last quarter. KVP Capital Advisors LP acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $4,626,000. XTX Topco Ltd bought a new position in Disc Medicine in the 4th quarter worth approximately $1,834,000. VARCOV Co. bought a new position in Disc Medicine in the 4th quarter worth approximately $423,000. Finally, Vestal Point Capital LP lifted its holdings in Disc Medicine by 47.0% during the 4th quarter. Vestal Point Capital LP now owns 735,000 shares of the company’s stock worth $58,366,000 after buying an additional 235,000 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider William Jacob Savage sold 5,731 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the sale, the insider directly owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 9,700 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00. Following the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $3,947,181.84. This represents a 15.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 85,000 shares of company stock worth $5,956,865 over the last quarter. Insiders own 3.76% of the company’s stock.

Disc Medicine Price Performance

IRON opened at $79.70 on Tuesday. The company has a fifty day moving average price of $69.53 and a two-hundred day moving average price of $70.18. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The firm has a market capitalization of $3.04 billion, a PE ratio of -11.96 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, analysts anticipate that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Morgan Stanley boosted their price objective on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Wedbush restated an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.44.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.